AIDS and HIV infection: estimates of the magnitude of the problem worldwide in 1985/1986.

Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

AIDS and HIV infection: estimates of the magnitude of the problem worldwide in 1985/1986.

Clin Immunol Immunopathol. 1987 Dec;45(3):297-309. Unique Identifier : AIDSLINE MED/88053509
Biggar RJ; Environmental Epidemiology Branch, National Cancer Institute,; Bethesda, Maryland 20892.

Abstract: This review summarizes observations about the distribution of AIDS and HIV infection throughout the world. The United States has reported the greatest number of cases to the World Health Organization (WHO), but data from many areas are lacking or incomplete, making comparisons between different areas unreliable. Even within the United States, data are difficult to interpret and require careful consideration of the size of the various HIV-risk groups in the population and the degree to which results of studies of selected cohorts within a risk group can be extrapolated to the whole of that population. Outside of the United States, Europe, and Australia, less information is available. Almost every country in South America has reported cases of AIDS, although in most reports the number is small. In Asia, many countries have not yet reported cases or have had only a small number of cases. By the end of 1986, many countries in Africa had not yet reported any AIDS cases to the WHO, even from areas where AIDS is known to occur (i.e., Zaire). However, there is ample evidence from regional studies in Africa that AIDS and HIV infection are a major public health problem. Using admittedly questionable information for estimating the size of the problem worldwide, I project that between two and three million persons worldwide were infected with HIV by 1985/1986. Despite the lack of an effective therapy or vaccine, much can be and is being done to limit the global spread of HIV infection and AIDS.

Keywords: Acquired Immunodeficiency Syndrome/*EPIDEMIOLOGY Africa Asia Australia Europe Human HIV Seropositivity/EPIDEMIOLOGY North America South America West Indies JOURNAL ARTICLE

880330
M8830396

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .